440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer

by Wei Wang, Peng Gao, Lu Sun, Guo Gui Sun, Jing Hao Jia, Xue Min Yao, Ming Da Chen, Wei Nan Yao
Published 2020-11-01

Development of R8 modified epirubicin–dihydroartemisinin liposomes for treatment of non-small-cell lung cancer

by Jing-Jing Liu, Wei Tang, Min Fu, Xiao-Qing Gong, Liang Kong, Xue-Min Yao, Ming Jing, Fu-Yi Cai, Xue-Tao Li, Rui-Jun Ju
Published 2019-12-01